225 related articles for article (PubMed ID: 23541563)
1. Large-scale independent validation of the nuclear factor-kappa B p65 prognostic biomarker in prostate cancer.
Gannon PO; Lessard L; Stevens LM; Forest V; Bégin LR; Minner S; Tennstedt P; Schlomm T; Mes-Masson AM; Saad F
Eur J Cancer; 2013 Jul; 49(10):2441-8. PubMed ID: 23541563
[TBL] [Abstract][Full Text] [Related]
2. Use of Gleason score, prostate specific antigen, seminal vesicle and margin status to predict biochemical failure after radical prostatectomy.
Blute ML; Bergstralh EJ; Iocca A; Scherer B; Zincke H
J Urol; 2001 Jan; 165(1):119-25. PubMed ID: 11125379
[TBL] [Abstract][Full Text] [Related]
3. Nuclear factor-kappaB nuclear localization is predictive of biochemical recurrence in patients with positive margin prostate cancer.
Fradet V; Lessard L; Bégin LR; Karakiewicz P; Masson AM; Saad F
Clin Cancer Res; 2004 Dec; 10(24):8460-4. PubMed ID: 15623625
[TBL] [Abstract][Full Text] [Related]
4. Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients.
Ploussard G; Agamy MA; Alenda O; Allory Y; Mouracade P; Vordos D; Hoznek A; Abbou CC; de la Taille A; Salomon L
BJU Int; 2011 Jun; 107(11):1748-54. PubMed ID: 20883488
[TBL] [Abstract][Full Text] [Related]
5. Nuclear localization of nuclear factor-kappaB p65 in primary prostate tumors is highly predictive of pelvic lymph node metastases.
Lessard L; Karakiewicz PI; Bellon-Gagnon P; Alam-Fahmy M; Ismail HA; Mes-Masson AM; Saad F
Clin Cancer Res; 2006 Oct; 12(19):5741-5. PubMed ID: 17020979
[TBL] [Abstract][Full Text] [Related]
6. Lymphovascular invasion is an independent prognostic factor in prostatic adenocarcinoma.
Cheng L; Jones TD; Lin H; Eble JN; Zeng G; Carr MD; Koch MO
J Urol; 2005 Dec; 174(6):2181-5. PubMed ID: 16280760
[TBL] [Abstract][Full Text] [Related]
7. Validation of the prognostic value of NF-κB p65 in prostate cancer: A retrospective study using a large multi-institutional cohort of the Canadian Prostate Cancer Biomarker Network.
Grosset AA; Ouellet V; Caron C; Fragoso G; Barrès V; Delvoye N; Latour M; Aprikian A; Bergeron A; Chevalier S; Fazli L; Fleshner N; Gleave M; Karakiewicz P; Lacombe L; Lattouf JB; van der Kwast T; Trudel D; Mes-Masson AM; Saad F;
PLoS Med; 2019 Jul; 16(7):e1002847. PubMed ID: 31265453
[TBL] [Abstract][Full Text] [Related]
8. Lack of association of prostate carcinoma nuclear grading with prostate specific antigen recurrence after radical prostatectomy.
Zhou M; Hayasaka S; Taylor JM; Shah R; Proverbs-Singh T; Manley S; Rubin MA
J Urol; 2001 Dec; 166(6):2193-7. PubMed ID: 11696734
[TBL] [Abstract][Full Text] [Related]
9. Caveolin-1 expression is a predictor of recurrence-free survival in pT2N0 prostate carcinoma diagnosed in Japanese patients.
Satoh T; Yang G; Egawa S; Addai J; Frolov A; Kuwao S; Timme TL; Baba S; Thompson TC
Cancer; 2003 Mar; 97(5):1225-33. PubMed ID: 12599229
[TBL] [Abstract][Full Text] [Related]
10. CD10 is inversely associated with nuclear factor-kappa B and predicts biochemical recurrence after radical prostatectomy.
Voutsadakis IA; Vlachostergios PJ; Daliani DD; Karasavvidou F; Kakkas G; Moutzouris G; Melekos MD; Papandreou CN
Urol Int; 2012; 88(2):158-64. PubMed ID: 22286396
[TBL] [Abstract][Full Text] [Related]
11. Predictors of prostate-specific antigen progression among men with seminal vesicle invasion at the time of radical prostatectomy.
Freedland SJ; Aronson WJ; Presti JC; Amling CL; Terris MK; Trock B; Kane CJ
Cancer; 2004 Apr; 100(8):1633-8. PubMed ID: 15073850
[TBL] [Abstract][Full Text] [Related]
12. Preoperative serum prostate specific antigen does not reflect biochemical failure rates after radical prostatectomy in men with large volume cancers.
Noguchi M; Stamey TA; McNeal JE; Yemoto CM
J Urol; 2000 Nov; 164(5):1596-600. PubMed ID: 11025712
[TBL] [Abstract][Full Text] [Related]
13. Prognostic significance of p53 nuclear accumulation in localized prostate cancer treated with radical prostatectomy.
Quinn DI; Henshall SM; Head DR; Golovsky D; Wilson JD; Brenner PC; Turner JJ; Delprado W; Finlayson JF; Stricker PD; Grygiel JJ; Sutherland RL
Cancer Res; 2000 Mar; 60(6):1585-94. PubMed ID: 10749127
[TBL] [Abstract][Full Text] [Related]
14. Is the GPSM scoring algorithm for patients with prostate cancer valid in the contemporary era?
Thompson RH; Blute ML; Slezak JM; Bergstralh EJ; Leibovich BC
J Urol; 2007 Aug; 178(2):459-63; discussion 463. PubMed ID: 17561132
[TBL] [Abstract][Full Text] [Related]
15. Nuclear factor-kappaB-mediated transforming growth factor-beta-induced expression of vimentin is an independent predictor of biochemical recurrence after radical prostatectomy.
Zhang Q; Helfand BT; Jang TL; Zhu LJ; Chen L; Yang XJ; Kozlowski J; Smith N; Kundu SD; Yang G; Raji AA; Javonovic B; Pins M; Lindholm P; Guo Y; Catalona WJ; Lee C
Clin Cancer Res; 2009 May; 15(10):3557-67. PubMed ID: 19447876
[TBL] [Abstract][Full Text] [Related]
16. Radical prostatectomy represents an effective treatment in patients with specimen-confined high pathological Gleason score prostate cancer.
Lughezzani G; Gallina A; Larcher A; Briganti A; Capitanio U; Suardi N; Lista G; Abrate A; Sangalli MN; Buffi N; Cestari A; Guazzoni G; Rigatti P; Montorsi F
BJU Int; 2013 May; 111(5):723-30. PubMed ID: 22487441
[TBL] [Abstract][Full Text] [Related]
17. Comparison of preoperative prostate specific antigen density and prostate specific antigen for predicting recurrence after radical prostatectomy: results from the search data base.
Freedland SJ; Kane CJ; Presti JC; Terris MK; Amling CL; Dorey F; Aronson WJ
J Urol; 2003 Mar; 169(3):969-73. PubMed ID: 12576824
[TBL] [Abstract][Full Text] [Related]
18. Nomogram predicting the probability of early recurrence after radical prostatectomy for prostate cancer.
Walz J; Chun FK; Klein EA; Reuther A; Saad F; Graefen M; Huland H; Karakiewicz PI
J Urol; 2009 Feb; 181(2):601-7; discussion 607-8. PubMed ID: 19084864
[TBL] [Abstract][Full Text] [Related]
19. Invasion of seminal vesicles by adenocarcinoma of the prostate: PSA outcome determined by preoperative and postoperative factors.
Bloom KD; Richie JP; Schultz D; Renshaw A; Saegaert T; D'amico AV
Urology; 2004 Feb; 63(2):333-6. PubMed ID: 14972484
[TBL] [Abstract][Full Text] [Related]
20. Low AZGP1 expression predicts for recurrence in margin-positive, localized prostate cancer.
Yip PY; Kench JG; Rasiah KK; Benito RP; Lee CS; Stricker PD; Henshall SM; Sutherland RL; Horvath LG
Prostate; 2011 Nov; 71(15):1638-45. PubMed ID: 21432866
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
